First patient dosed in phase 2/3 trial of advanced HCC therapy - Hallo friendsTHE LEK NEWS, In the article you read this time with the title First patient dosed in phase 2/3 trial of advanced HCC therapy, We have prepared this article for you to read and retrieve information therein. Hopefully the contents of postings Article culture, Article economy, Article health, Article healthy tips, Article news, Article politics, Article sports, We write this you can understand. Alright, good read.

Title : First patient dosed in phase 2/3 trial of advanced HCC therapy
link : First patient dosed in phase 2/3 trial of advanced HCC therapy

First patient dosed in phase 2/3 trial of advanced HCC therapy

First patient dosed in phase 2/3 trial of advanced HCC therapy
March 3, 2019

Innovent Biologics announced first patient dosing in a phase 2/3 trial of Tyvyt with IBI305 for patients with advanced hepatocellular carcinoma taking place in China, according to a press release.

"HCC is the fourth most common cancer and the second leading cause of cancer related death in China,” Fan Jia, president of Zhongshan Hospital, said in the release. “The five-year survival rate is about 10%, and only 20-30% of patients have the opportunity for curative surgery. Current targeted therapies have only shown limited responses in HCC. Immune checkpoint inhibitors have brought new hope to patients with this life-threatening disease.”

Continue reading article...

Thus Article First patient dosed in phase 2/3 trial of advanced HCC therapy

That's an article First patient dosed in phase 2/3 trial of advanced HCC therapy This time, hopefully can give benefits to all of you. well, see you in posting other articles.

You are now reading the article First patient dosed in phase 2/3 trial of advanced HCC therapy with the link address https://theleknews.blogspot.com/2019/03/first-patient-dosed-in-phase-23-trial.html

Tweet

Subscribe to receive free email updates: